Eugene J. McDonald Joins Board of Incara Pharmaceuticals

Apr 20, 2001, 01:00 ET from Incara Pharmaceuticals Corporation

    RESEARCH TRIANGLE PARK, N.C., April 20 /PRNewswire/ --
     Incara Pharmaceuticals Corporation (Nasdaq:   INCR) announced today that
 Eugene J. McDonald, Executive Vice President, Office of Investment Counsel at
 Duke University, has been elected to the company's Board of Directors.  Mr.
 McDonald founded and was the first president and CEO of Duke Management
 Company, the investment management affiliate of Duke University.
     Mr. McDonald has served at Duke University for more than two decades.  In
 addition to his current position and his role in founding Duke Management
 Company, Mr. McDonald was Duke's Chief Financial/Administrative Officer from
 1984 to 1990, and, prior to this, served as Vice President and University
 Counsel.  He began his career as professor of law at Georgetown Law School,
 and as an attorney in the corporate/business practice of Brobeck, Phleger and
 Harrison in San Francisco.
     Mr. McDonald is the lead director of the Deutsche Bank/Alex Brown Fund
 Family, and also serves on the boards of directors of Red Hat, Inc. and
 National Commerce Bank Corporation.  He has also served on a number of
 advisory boards, including those of the New York Stock Exchange's PMAC
 Committee and T. Rowe Price Strategic Partners.  Mr. McDonald received his
 undergraduate and law degrees from the University of San Francisco.
     "I have known the management of Incara, both professionally and
 personally, for over ten years," Mr. McDonald stated.  "In that time they have
 shown an ability to identify and develop innovative technologies in the
 biotechnology field.  This is an exciting time for Incara, as it has
 interesting technologies that could become important therapies.  I'm pleased
 to become a part of the team."
     "Gene McDonald has outstanding credentials, including his experience
 overseeing the investments of one of the largest university endowments in the
 country," commented Clayton I. Duncan, President and CEO of Incara.  "His
 expertise in the investment and capital markets will be valuable for Incara,
 and we are delighted to have him join our Board of Directors."
     Incara Pharmaceuticals Corporation (www.incara.com) focuses on the
 protection and regeneration of tissue damaged by injury and disease.  The
 company currently has programs in three areas: liver stem and progenitor cell
 therapy as a treatment for liver failure; catalytic antioxidants as treatment
 for stroke and other tissue damage; and OP2000, an ultra-low molecular weight
 heparin being developed with Elan Corporation for treatment of ulcerative
 colitis.
     The statements in this press release that are not purely statements of
 historical fact are forward-looking statements, and actual results might
 differ materially from those anticipated.  These statements and other
 statements made elsewhere by the company or its representatives, which are
 identified or qualified by words such as "intends," "likely," "will,"
 "suggests," "expects," "might," "may," "believe," "could," "should," "would,"
 "anticipates" or "plans," the negative of those terms or similar expressions,
 are based on a number of assumptions that are subject to risks and
 uncertainties.  Important factors that could cause results to differ include
 risks associated with the need to obtain funds for operations, uncertainties
 of scientific research, clinical trials and product development activities.
 These and other important risks are described in Incara's reports on Form
 10-K, Form 10-Q and Form 8-K and its registration statements filed with the
 Securities and Exchange Commission.  Readers are cautioned not to place undue
 reliance on these forward-looking statements, which speak only as of the date
 hereof.  The company assumes no obligation to update the information in this
 release.
 
 

SOURCE Incara Pharmaceuticals Corporation
    RESEARCH TRIANGLE PARK, N.C., April 20 /PRNewswire/ --
     Incara Pharmaceuticals Corporation (Nasdaq:   INCR) announced today that
 Eugene J. McDonald, Executive Vice President, Office of Investment Counsel at
 Duke University, has been elected to the company's Board of Directors.  Mr.
 McDonald founded and was the first president and CEO of Duke Management
 Company, the investment management affiliate of Duke University.
     Mr. McDonald has served at Duke University for more than two decades.  In
 addition to his current position and his role in founding Duke Management
 Company, Mr. McDonald was Duke's Chief Financial/Administrative Officer from
 1984 to 1990, and, prior to this, served as Vice President and University
 Counsel.  He began his career as professor of law at Georgetown Law School,
 and as an attorney in the corporate/business practice of Brobeck, Phleger and
 Harrison in San Francisco.
     Mr. McDonald is the lead director of the Deutsche Bank/Alex Brown Fund
 Family, and also serves on the boards of directors of Red Hat, Inc. and
 National Commerce Bank Corporation.  He has also served on a number of
 advisory boards, including those of the New York Stock Exchange's PMAC
 Committee and T. Rowe Price Strategic Partners.  Mr. McDonald received his
 undergraduate and law degrees from the University of San Francisco.
     "I have known the management of Incara, both professionally and
 personally, for over ten years," Mr. McDonald stated.  "In that time they have
 shown an ability to identify and develop innovative technologies in the
 biotechnology field.  This is an exciting time for Incara, as it has
 interesting technologies that could become important therapies.  I'm pleased
 to become a part of the team."
     "Gene McDonald has outstanding credentials, including his experience
 overseeing the investments of one of the largest university endowments in the
 country," commented Clayton I. Duncan, President and CEO of Incara.  "His
 expertise in the investment and capital markets will be valuable for Incara,
 and we are delighted to have him join our Board of Directors."
     Incara Pharmaceuticals Corporation (www.incara.com) focuses on the
 protection and regeneration of tissue damaged by injury and disease.  The
 company currently has programs in three areas: liver stem and progenitor cell
 therapy as a treatment for liver failure; catalytic antioxidants as treatment
 for stroke and other tissue damage; and OP2000, an ultra-low molecular weight
 heparin being developed with Elan Corporation for treatment of ulcerative
 colitis.
     The statements in this press release that are not purely statements of
 historical fact are forward-looking statements, and actual results might
 differ materially from those anticipated.  These statements and other
 statements made elsewhere by the company or its representatives, which are
 identified or qualified by words such as "intends," "likely," "will,"
 "suggests," "expects," "might," "may," "believe," "could," "should," "would,"
 "anticipates" or "plans," the negative of those terms or similar expressions,
 are based on a number of assumptions that are subject to risks and
 uncertainties.  Important factors that could cause results to differ include
 risks associated with the need to obtain funds for operations, uncertainties
 of scientific research, clinical trials and product development activities.
 These and other important risks are described in Incara's reports on Form
 10-K, Form 10-Q and Form 8-K and its registration statements filed with the
 Securities and Exchange Commission.  Readers are cautioned not to place undue
 reliance on these forward-looking statements, which speak only as of the date
 hereof.  The company assumes no obligation to update the information in this
 release.
 
 SOURCE  Incara Pharmaceuticals Corporation